Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial
一项针对18-55岁或≥56岁成年人的随机、双盲、安慰剂对照I期临床试验的12个月结果显示，MF59佐剂增强的SARS-CoV-2刺突糖蛋白钳疫苗具有长期安全性和免疫原性。
期刊:EBioMedicine
影响因子:10.8
doi:10.1016/j.ebiom.2023.104842
Chappell, Keith J; Mordant, Francesca L; Amarilla, Alberto A; Modhiran, Naphak; Liang, Benjamin; Li, Zheyi; Wijesundara, Danushka K; Lackenby, Julia A; Griffin, Paul; Bennet, Jillian K; Hensen, Luca; Zhang, Wuji; Nguyen, Thi H O; Tran, Mai H; Tapley, Peter; Barnes, James; Reading, Patrick C; Kedzierska, Katherine; Ranasinghe, Charani; Subbarao, Kanta; Watterson, Daniel; Young, Paul R; Munro, Trent P
